1. Home
  2. HQI vs IFRX Comparison

HQI vs IFRX Comparison

Compare HQI & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HireQuest Inc. (DE)

HQI

HireQuest Inc. (DE)

N/A

Current Price

$14.35

Market Cap

232.1M

ML Signal

N/A

Logo InflaRx N.V.

IFRX

InflaRx N.V.

N/A

Current Price

$1.18

Market Cap

225.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HQI
IFRX
Founded
2002
2007
Country
United States
Germany
Employees
75000
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
232.1M
225.5M
IPO Year
2008
2017

Fundamental Metrics

Financial Performance
Metric
HQI
IFRX
Price
$14.35
$1.18
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
★ $20.50
$8.41
AVG Volume (30 Days)
22.4K
★ 1.1M
Earning Date
11-12-2026
11-03-2026
Dividend Yield
★ 1.29%
N/A
EPS Growth
★ 73.08
N/A
EPS
★ 0.31
N/A
Revenue
★ $30,640,000.00
N/A
Revenue This Year
$0.54
N/A
Revenue Next Year
$5.47
N/A
P/E Ratio
$59.74
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$7.38
$0.80
52 Week High
$20.84
$2.95

Technical Indicators

Market Signals
Indicator
HQI
IFRX
Relative Strength Index (RSI) 32.65 31.08
Support Level $12.14 $0.81
Resistance Level $18.52 $2.44
Average True Range (ATR) 1.30 0.15
MACD -0.08 -0.03
Stochastic Oscillator 24.31 3.12

Price Performance

Historical Comparison
HQI
IFRX

About HQI HireQuest Inc. (DE)

HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: